Narrow Your Results
A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations
This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningioma that is growing, spreading, or getting worse. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
A221208: Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in...
DNAtrix: A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of this Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus...
Brain Cancer BMS 498: A Randomized Phase III Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma
The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving nivolumab every two weeks in addition to radiation therapy (RT), and then every four weeks, compared with patients receiving standard therapy with temozolomide in addition to RT.
Brain Cancer BMSCA209-548: A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy Combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor06-methyguanine DNA Methyltransferase) Glioblastoma
The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving temozolomide plus radiation therapy compared with patients receiving nivolumab in addition to temozolomide plus radiation therapy.
Brain Cancer A071102: A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
The purpose of the screening research study is to examine brain cancer patients’ surgically removed tumors for certain molecular changes that may make them eligible to participate in the related treatment study. The purpose of the treatment research study is to compare the effects (good and bad) of the usual treatment (temozolomide) with or without the...
ANBL00B1 Study to bank tumor samples from patients with Neuroblastoma (PRO00000544)
ACNS0332: Medulloblastoma/PNET study PRO00000577
The primary goals are to determine whether carboplatin radiosensitization increases long-term, event-free survival of pediatric patients with newly diagnosed, previously untreated, high-risk medulloblastoma or supratentorial primitive neuroectodermal tumors; and to determine whether isotretinoin increases long-term, event-free survival of these...
Brain Cancer A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme
The purpose of this study is to see if taking armodafinil at a dose of 150 mg or 250 mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue. Another purpose of the study is to determine the side effects of taking armodafinil compared to placebo (inactive drug) on cancer-related fatigue....
ACNS02B3 Pediatric brain tumor specimen banking (PRO00001093)
The purpose of this study is to collect brain tumor specimens from patients treated at Children's Oncology Group (COG) institutions for long-term repository storage. The repository will be made available to qualified researchers to aid in understanding the biology of pediatric brain tumors.